Pantothenic Acid
Evidence Fact Sheet
Vitamin B5
Pantothenic acid (vitamin B5) is an essential precursor of Coenzyme A central to energy metabolism. EFSA authorizes four maintenance-function claims; the lipid evidence belongs to pantethine (a distinct molecule) and skin evidence to topical panthenol — neither transfers to oral B5. Adult reference intake ~5 mg/day; no UL set.
Also known as: Vitamin B5 · Calcium D-pantothenate · D-Pantothenic acid · Dexpanthenol (topical derivative) · Panthenol (topical derivative) · Pantethine (disulfide active form · separate molecule)
Overview
Pantothenic acid (vitamin B5) is a water-soluble B-vitamin and the essential precursor of Coenzyme A (CoA) and acyl carrier protein, cofactors that connect carbohydrate, fat, and amino-acid energy metabolism. It is widely distributed in food, so clinical deficiency is rare; the adult reference (adequate) intake is ~5 mg/day across CN/US/EU, and no Tolerable Upper Intake Level has been set in any of the four markets. In the EU, EFSA authorizes four Article 13(1) maintenance-function claims (normal energy-yielding metabolism, reduction of tiredness and fatigue, normal mental performance, and normal synthesis of steroid hormones/vitamin D/some neurotransmitters); in the US calcium pantothenate is GRAS (21 CFR 184.1212) and a lawful dietary ingredient under DSHEA. Two strict boundaries govern the evidence: pantethine (the disulfide form) is a separate molecule with its own lipid pharmacology, and topical dexpanthenol/panthenol is a cosmetic/OTC route — neither body of evidence transfers to oral B5 itself.
Mechanism of Action
Essential precursor of Coenzyme A (CoA), the cofactor for >70 enzymatic reactions connecting carbohydrate, fat, and amino-acid energy metabolism (research-context mechanism) · Constituent of acyl carrier protein (ACP), a cofactor of fatty-acid synthase (FAS) · Cofactor implicated in synthesis of steroid hormones, vitamin D, and some neurotransmitters (acetylcholine/serotonin) — the basis of the EFSA Article 13.1 authorized function wording · Pantethine (the disulfide active form · a distinct molecule, NOT pantothenic acid itself) has a separate research-context lipid-modulating pathway involving HMG-CoA reductase — evidence does NOT transfer to the parent vitamin · Topical dexpanthenol/panthenol research describes skin-barrier and moisturization effects via a cosmetic/OTC route that is mechanistically and regulatorily separate from oral B5
Body systems: Mitochondrial & Cellular Energy · Endocrine & Metabolic · Skin & Connective Tissue · Mood & Stress Response · Cellular Renewal
Evidence-Based Benefits
Each benefit below is anchored to a specific PubMed-indexed study. Effect sizes, sample sizes, and p-values are reported as published; no values are inferred. Honest negatives and null results are kept alongside the positive findings, and disease-research populations are described as such — Pantothenic Acid is not characterized as a treatment for any disease.
Acne (Oral B5 Supplement)
RCT supported- P = 0.0197total lesion count vs placebo · wk 12
- 48 enrolled / 41 evaluablerandomized DB placebo-controlled
This is the strongest human trial of an actual oral pantothenic-acid-based supplement (rather than a distinct B5 derivative). In a randomized, double-blind, placebo-controlled study of mild-to-moderate facial acne, the supplement group showed a significant mean reduction in total facial lesion count versus placebo at week 12. The card's overall grade remains C because single-vitamin B5 monotherapy efficacy evidence is otherwise sparse.
Reported effect: Significant mean reduction in total lesion count vs placebo at week 12, P = 0.0197; 48 enrolled, 41 evaluable
“There was a significant mean reduction in total lesion count in the pantothenic acid group versus placebo at week 12 (P = 0.0197).”
Source: PMID 24831048 · Yang 2014 · Dermatol Ther (Heidelb)
Blood Lipids — PANTETHINE (Separate Molecule, Does NOT Transfer to B5)
RCT supported- 11% LDL-C decreasepantethine vs baseline
- P = 0.006LDL-C vs placebo · wk 16
- 32 subjectstriple-blind diet-controlled
Pantethine is the disulfide form of vitamin B5 — a distinct molecule with its own lipid pharmacology — so this evidence must NOT be attributed to plain pantothenic acid/calcium pantothenate. In low-to-moderate cardiovascular-risk adults eligible for statin therapy, pantethine (600 mg/day then 900 mg/day) significantly lowered LDL-C versus placebo.
Reported effect: 11% decrease in LDL-C from baseline on pantethine; significant vs placebo at 16 weeks (P=0.006); n=32
“An 11% decrease in LDL-C from baseline was seen in participants on pantethine... Compared with placebo, the participants on pantethine showed a significant decrease in total cholesterol at 16 weeks (P=0.040) and LDL-C at 8 and 16 weeks (P=0.020 and P=0.006, respectively).”
Source: PMID 24600231 · Evans 2014 · Vasc Health Risk Manag
Triglycerides — Coenzyme a vs PANTETHINE (B5 Derivatives, Not B5)
RCT supported- 33.3% vs 16.5%TG reduction · CoA vs pantethine · wk 8
- P < .001between-group · 8 weeks
- 216 subjectsrandomized double-blind multicenter
A head-to-head trial of two B5-related actives — Coenzyme A and pantethine — in hyperlipidemia, not of pantothenic acid itself. Coenzyme A produced a greater triglyceride reduction than pantethine at 8 weeks. Like the pantethine lipid data, this does not transfer to ordinary oral vitamin B5.
Reported effect: TG reduction 33.3% (CoA) vs 16.5% (pantethine) at 8 weeks; between-group P < .001; n=216
“TG reduction was 26.0% with CoA and 17.4% with pantethine after 4 weeks and 33.3% and 16.5% after 8 weeks... The difference between the 2 groups was significant at both 4 weeks (P = .0413) and 8 weeks (P < .001).”
Source: PMID 26350816 · Chen 2015 · J Clin Lipidol
Exercise Performance / Anti-Fatigue (Honest Negative)
Null / no benefit RCT supported- P = 0.582000-m time trial · NS
- 6 cyclistsrandomized crossover
A prominent honest negative for the energy/anti-fatigue use case. In highly trained cyclists, supplementation with a thiamin derivative plus pantethine did NOT alter exercise metabolism or performance — the 2000-m time trial did not differ from placebo. EFSA's energy/fatigue claims are maintenance (nutritional adequacy) statements, not demonstrations of a performance benefit from extra B5.
Reported effect: 2000-m time trial not significantly different (placebo 178.2 s vs treatment 170.7 s; P=0.58); n=6
“Time to complete the 2000-m time trial was also not significantly different between experimental conditions [PL 178.2 (8.4), AP 170.7 (10.2) s; P=0.58].”
Source: PMID 9650731 · Webster 1998 · Eur J Appl Physiol Occup Physiol
Topical Skin Barrier — PANTHENOL (Cosmetic Route, Not Oral B5)
RCT supported- D3 / D7 / D14TEWL timepoints reduced
Topical panthenol/dexpanthenol works via a cosmetic/OTC skin-barrier route that is mechanistically and regulatorily separate from oral B5 — the evidence must not be attributed to oral supplements. This double-blind RCT of a panthenol-enriched mask after facial laser treatment reported reduced transepidermal water loss in the active group, but the abstract states direction only, so no effect-size number is extracted here.
Effect size: this study reports the direction of the finding but does not state a specific numeric effect size, so none is given here rather than estimated.
“transepidermal water loss (TEWL) was significantly reduced in the MG at D3, D7, and D14.”
Source: PMID 40613435 · Gao 2025 · J Cosmet Dermatol
Dosage (research context · not a recommendation)
Reference intake (adequate intake) for adults is 5 mg/day across CN RNI / US IOM AI / EFSA DRV. No Tolerable Upper Intake Level (UL) has been set in any of the four markets (CN/US/BR/EU). Marketplace products (DSLD median ~500 mg/day) commonly exceed the reference intake by ~100x with no established toxicity, but research demonstrating added benefit above the reference intake for healthy individuals is lacking. Note: lipid-research doses of 600-900 mg/day apply to PANTETHINE (a separate disulfide molecule), NOT to pantothenic acid itself.
Regulatory Status · 4 Markets
- US · FDA
- United States (FDA): Calcium pantothenate is GRAS by regulation under 21 CFR 184.1212 (since 1984). Lawful dietary ingredient under DSHEA 1994 (~194 products in DSLD, median ~500 mg/day). Structure/function claims are permitted with the mandatory disclaimer 'This statement has not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.' US IOM Adequate Intake (AI) for adults is 5 mg/day; no UL established. No 21 CFR Part 101 Subpart E Significant Scientific Agreement health claim exists for pantothenic acid.
- EU · EFSA
- European Union (EFSA / Reg 432/2012): Pantothenic acid has FOUR authorized Article 13(1) general-function health claims in the Annex to Commission Regulation (EU) No 432/2012 — (1) contributes to normal energy-yielding metabolism; (2) contributes to the reduction of tiredness and fatigue; (3) contributes to normal mental performance; (4) contributes to normal synthesis and metabolism of steroid hormones, vitamin D and some neurotransmitters. Conditions of use: the claim may be used only for food which is at least a source of pantothenic acid (>=15% NRV per 100 g/mL or per portion; i.e. >=0.9 mg/day). Permitted supplement forms under Directive 2002/46/EC Annex I include calcium pantothenate, sodium pantothenate, and panthenol/dexpanthenol. DRV AI for adults is 5 mg/day (EFSA 2014); no UL set (EFSA 2006).
- CN · China
- Established nutrient — listed in the SAMR Health Food Raw Material Catalog (nutrient supplements, 2020 ed.) as calcium D-pantothenate / sodium pantothenate, and permitted under GB 14880 food-fortifier and GB 2760 standards; filing pathway available (adult RNI 5 mg/day; no UL set).
- BR · ANVISA
- Brasil (ANVISA): Acido pantotenico (vitamina B5) e constituinte autorizado de suplementos alimentares sob RDC 243/2018, com limites minimos/maximos de ingestao diaria regulados pela IN 28/2018 (Anexos III/IV). Alegacoes de propriedade funcional, quando aplicaveis, seguem o padrao verbatim oficial do Anexo V e devem ser usadas sem reescrita Sem UL estabelecido.
Authorized Claims
EFSA — “Pantothenic acid contributes to normal energy-yielding metabolism” (Reg (EU) 432/2012 Annex)
EFSA — “Pantothenic acid contributes to normal energy-yielding metabolism” (Reg 432/2012)
EFSA — “Pantothenic acid contributes to the reduction of tiredness and fatigue” (Reg 432/2012)
EFSA — “Pantothenic acid contributes to normal mental performance” (Reg 432/2012)
EFSA — “Pantothenic acid contributes to normal synthesis and metabolism of steroid hormones, vitamin D and some neurotransmitters” (Reg 432/2012)
Safety
Water-soluble vitamin cleared renally; among the highest safety margins of the B-vitamin family — no UL set in CN/US/BR/EU and no established drug-nutrient interactions. Very high oral doses (>10 g/day, e.g. historical high-dose acne hypothesis doses) have occasionally been associated with diarrhea / GI upset. Clinical deficiency is extremely rare given wide dietary distribution. Two strict form/route boundaries apply: (1) Pantethine is the disulfide active form — a separate molecule with its own lipid pharmacology; lipid data must NOT be attributed to pantothenic acid itself. (2) Topical dexpanthenol/panthenol skin-barrier evidence follows a cosmetic/OTC route and must NOT be attributed to oral B5 supplements. PKAN (pantothenate-kinase-associated neurodegeneration) is a rare orphan disease and is NOT a supplement indication.
Related
Goals: skin-beauty · heart-health
Lifestyles: senior-60-plus
References
PubMed-indexed citations anchoring the benefit findings above. Effect sizes are reported as published.
- PMID 24831048 · Yang 2014 · Dermatol Ther (Heidelb) — Acne (Oral B5 Supplement)
- PMID 24600231 · Evans 2014 · Vasc Health Risk Manag — Blood Lipids — PANTETHINE (Separate Molecule, Does NOT Transfer to B5)
- PMID 26350816 · Chen 2015 · J Clin Lipidol — Triglycerides — Coenzyme a vs PANTETHINE (B5 Derivatives, Not B5)
- PMID 9650731 · Webster 1998 · Eur J Appl Physiol Occup Physiol — Exercise Performance / Anti-Fatigue (Honest Negative)
- PMID 40613435 · Gao 2025 · J Cosmet Dermatol — Topical Skin Barrier — PANTHENOL (Cosmetic Route, Not Oral B5)
Frequently Asked Questions
1. Does taking extra vitamin B5 (pantothenic acid) lower cholesterol?
Not as evidenced for plain vitamin B5 itself. The cholesterol and triglyceride findings come from pantethine and Coenzyme A — distinct B5-related molecules with their own pharmacology (e.g. an 11% LDL-C decrease with pantethine, P=0.006, in Evans 2014, PMID 24600231; a 33.3% triglyceride reduction with Coenzyme A in Chen 2015, PMID 26350816). The card explicitly flags that this evidence does not transfer to ordinary oral pantothenic acid or calcium pantothenate.
2. Is there real human evidence for oral B5 itself?
The strongest trial of an actual oral pantothenic-acid-based supplement is an acne RCT (Yang 2014, PMID 24831048), which found a significant reduction in total facial lesion count versus placebo at week 12 (P = 0.0197). Beyond that, single-vitamin B5 monotherapy efficacy evidence is sparse, which is why the card carries an overall evidence grade of C.
3. Does B5 boost energy or fight fatigue?
EFSA authorizes maintenance-function claims (normal energy-yielding metabolism, reduction of tiredness and fatigue) because B5 is a required cofactor, but those are nutritional-adequacy statements, not proof that extra B5 enhances performance. A randomized crossover trial in cyclists found no performance benefit — the 2000-m time trial did not differ from placebo (P=0.58; Webster 1998, PMID 9650731).
4. Is high-dose B5 safe?
Vitamin B5 is water-soluble and renally cleared, with among the highest safety margins of the B-vitamins — no Tolerable Upper Intake Level has been set in the US, EU, China, or Brazil, against an adult reference intake of about 5 mg/day. Marketplace products often far exceed that intake without established toxicity, though very high oral doses have occasionally been associated with GI upset. This is evidence reporting, not dosing guidance.
Last evidence review: 2026-06-13